Upadacitinib 30 mg Emerges as Most Effective Oral JAK Inhibitor for Moderate-to-Severe Atopic Dermatitis in Bayesian Meta-Analysis
A Bayesian network meta-analysis suggests that upadacitinib 30 mg provides the highest short-term efficacy among oral Janus kinase (JAK) inhibitors for moderate-to-severe atopic dermatitis (AD), outperforming other agents across key clinical endpoints.
This PRISMA-compliant systematic review included 9 randomized, double-blind, placebo-controlled trials comprising 4261 patients. Treatments evaluated included upadacitinib (15 mg, 30 mg), abrocitinib (100 mg, 200 mg), baricitinib (2 mg, 4 mg), and ivarmacitinib (4 mg, 8 mg). Primary outcomes included Eczema Area and Severity Index (EASI)-75, Investigator’s Global Assessment (IGA-AD 0/1), and ≥4-point improvement in Itch Numerical Rating Scale (NRS) at 12 to 16 weeks.
Across all endpoints, upadacitinib 30 mg consistently ranked highest. Upadacitinib 30 mg demonstrated the greatest odds of achieving EASI-75, IGA-AD 0/1, and significant itch reduction compared with placebo and other JAK inhibitors. Upadacitinib 15 mg and abrocitinib 200 mg followed as next most effective options.
The treatment hierarchy remained consistent across efficacy measures, with higher surface under the cumulative ranking values indicating greater probability of being the most effective therapy. This consistent ranking across endpoints supports the robustness of the findings.
“This Bayesian network meta-analysis demonstrates that upadacitinib 30 mg provides the greatest short-term efficacy among oral JAK inhibitors for moderate-to-severe AD,” the authors concluded. “These findings establish a clear efficacy hierarchy and support preferential consideration of upadacitinib when oral JAK inhibitor therapy is indicated.”
These results provide clinicians with comparative evidence to guide treatment selection among oral JAK inhibitors, particularly when rapid and high-level disease control is desired.
Reference
Babul A, Mehta D, Soliman Y, et al. Upadacitinib leads in efficacy: Bayesian network meta-analysis of four JAK inhibitors for moderate-to-severe atopic dermatitis. Presented at: American Academy of Dermatology Annual Meeting; March 27–31, 2026; Denver, Colorado.
